rss

Recent eLetters

Displaying 1-9 letters out of 396 published

  1. Re:Bauld et al omit evidence on passive exposure to e-cigarette aerosol

    NOT PEER REVIEWED David Bareham cites 'Rip Tripper' as evidence that e-cigarette users report experiences of allergies being exacerbated in non users by vapour and describes Mr Tripper's subsequent rather mangled argument that the devices should not be used in enclosed public spaces as "eloquent".

    Perhaps Mr Bareham is unaware that Mr Tripper has also claimed that vaping causes limb cramps and dry knuckles which was a surprise to most vapers, until they spotted the affiliate link to where they could purchase electrolytes and a lotion to 'cure' them (1).

    (1) 'Rip Trippers exposed as a sellout' Jh Reviews https://youtu.be/F1EJkbM0m7g (contains profanity)

    Conflict of Interest:

    I am a trustee of NNA(UK) which is a consumer driven charity which aims to improve health by increasing awareness and understanding of reduced risk alternatives to smoked tobacco.

    Read all letters published for this article

    Submit response
  2. Methodological pitfalls in the measurement and decomposition of socioeconomic inequality of smoke exposure

    NOT PEER REVIEWED I would like to point out a few disturbing inaccuracies in the methodology and interpretation. Since the health variable is binary, the authors apply "Wagstaff's correction" to the Concentration Index. This is a perfectly legitimate decision, but the authors mistakenly suggest that this correction can be applied to both the relative and the absolute version of the index, yielding two normalized indices. In fact, there is only one Wagstaff index, which can be expressed as W = RC/(1-m) = AC/[m(1-m)], with m = prevalence. All the results which are presented under the heading "Absolute concentration index" in Table 2 and as "AC" in Table 3 are therefore irrelevant. These results refer to the index mW which nobody has ever used in the literature. It follows that the decomposition formula (6) of the paper is redundant. Similar remarks hold for the application of the alternative "Erreygers correction". The correction leads to one index, not two as suggested by the authors. The index can be written as E = 4mRC = 4AC. As a consequence, the results presented under the heading "Absolute concentration index" in Table A.1 of the supplementary online material are irrelevant. They refer to the index mE, which is not the one defined by Erreygers. After a brief comparison of the Wagstaff and Erreygers indices the authors conclude that "the calculated RC and AC informed qualitatively similar inference" (p. 9). Since E = 4m(1-m)W, the values of E and W clearly will be positively correlated, and the more strongly so if the variation in prevalence is limited. For the whole population, the (unweighted) average of m is 0.28, and the standard deviation 0.19. As expected, the correlation of E and W is high, but not perfect: the coefficient of correlation is 0.8815, and the rank correlation coefficient 0.8726. Nevertheless, countries such as Liberia, Bangladesh and Benin, make large jumps in the rankings if inequality is measured by one index rather than the other. At least for these countries, it may be doubted whether the results are "qualitatively similar". When it comes to the calculation of the between-group and within-group shares, it makes no difference whether the Wagstaff or Erreygers index is used. The main problem here is that any rank-dependent index is not subgroup decomposable. There is always a residual term, which may be quite large. Because of this, the decomposition results presented in the paper are unreliable.

    Conflict of Interest:

    None declared

    Read all letters published for this article

    Submit response
  3. Flavor Profiles

    NOT PEER REVIEWED When it comes to vaping my knowledge is somewhat advanced, in the hardware aspect I am in the forefront of technology, I test prototypes and beta models for manufacturers all around the globe, I also have acquired quite a bit of knowledge when it comes to the creation of flavors.

    There's a big difference between something you like and what is referred to an "All Day Vape" or ADV and the impact that has on quitting successfully is quite dramatic.

    I have this one flavor I make that I absolutely love, it's Caramel Apple Crumble with a bit of Creamy Custard, but like many other vapes it's just too decadent for anyone to vape all day much like chocolate flavors generally are. Just because you enjoy it doesn't mean you can tolerate it all day and that can determine your chances at a successful quit attempt.

    The flavors used in the study appear to be much generic to yield results that would reflect the current market as most of it is filled with much more complex mixes and many variations of each flavor..

    There are many variations of flavors that taste like different brands of cigarettes or candy and fruits, if a smoker were to try a tobacco blend that tasted like their brand of cigarette their chances at a successful quit attempt would be much higher than if they tried another variation.

    Flavor is by far the most important aspect of a successful quit attempt when it comes to vaping, once a person finds 1 or 2 flavors they can enjoy all day they then need to find a device with the vapor production they are looking for and the appropriate nicotine level to suit it.

    Personally when I first decided to give vaping a shot I tried over twenty flavors many of which I thought I would enjoy but didn't, I ended up with two flavors Strawberry Creme and Skittles, SBC all day and Sk when I felt like something a little more sweet...

    The ability to allow people to sample flavors is very much the key to their success, if I were not allowed and went with what I thought sounded good I would still be smoking today.

    Conflict of Interest:

    None declared

    Read all letters published for this article

    Submit response
  4. Bauld et al omit evidence on passive exposure to e-cigarette aerosol

    NOT PEER REVIEWED The American Indoor Hygiene Association (AIHA) i.e. Experts in in this particular field on passive exposure, have, previously, concluded conversely to Bauld et al (1). As they state:

    "If the only individual affected by using e-cigarettes were the vaper, the discussion could end here. That is not, however, the case. Similar to secondhand smoke, the ingredients exhaled by the vaper include nicotine, metals, flavorings, and glycol that accumulate in the ambient air. Recipients of secondhand vapor have not chosen to - many, in fact, have explicitly chosen not to - use e-cigarettes. The exposure to secondhand vapor, just like secondhand smoke, raises issues of involuntary exposure and competing rights. This is even more critical for groups that may be, and probably are, more susceptible to adverse effects of secondhand vapor, including children, pregnant women, and people with already compromised health, some of whom may have limited ability to leave the spaces in which vaping occurs or has occurred."

    This scientific postulation of second-hand inhalation of e-cigarette aerosol and subsequent adverse health effects has been further substantiated: via users of e-cigarettes, in their own personal, real- world experiences (2). They subsequently, and eloquently argue, that the devices should not be utilised in enclosed public spaces, due to these events occurring.

    Linda Bauld has previously argued in an extended article that:

    ". . . there is no good evidence that [second hand] exposure is harmful to bystanders . . . To argue otherwise is just factually incorrect." (3)

    However, the phrase "harmful to bystanders" provides a hyperlink to a review paper (4) of the potential for second hand exposures that, incongruently to Professor Bauld's claim, concludes that e-cigarettes:

    ". . . impart a LOWER potential disease burden than conventional TCs" (my emphasis)

    I.E. therefore, NOT zero potential disease burden.

    It is to be commended that Bauld et al wish to enhance the potential for adult smoking cessation maximally, however, in this case, there IS evidence that such a policy of non-restricted use potentially infringes the rights of non-users to avoid passive inhalation and subsequent adverse health effects, as the AIHA postulate, and as users of e-cigarettes have confirmed in real-world conditions.

    1) American Industrial Hygiene Association: https://www.aiha.org/government- affairs/Documents/Electronc%20Cig%20Document_Final.pdf

    2) "Vaping e-cigs in public" Available at: https://www.youtube.com/watch?v=6c5Ln69hWUc

    3) Linda Bauld (2015). Available at: https://www.theguardian.com/science/sifting-the- evidence/2015/feb/23/theres-no-evidence-e-cigarettes-are-as-harmful-as- smoking

    4) Oh, A. & Kacker, A. 2014 Do electronic cigarettes impart a lower potential disease burden than conventional tobacco cigarettes? Review on E-cigarette vapor versus tobacco smoke. Laryngoscope 124(12):2702-6. doi: 10.1002/lary.24750. Epub 2014 Oct 9.

    David Bareham

    "All views are my own and do not necessarily reflect those of my employer"

    Conflict of Interest:

    I have 3 presentations to local clinicians in Lincolnshire within the last 18 months entitled: "E-cigarettes: update on evidence", organised by GlaxoSmithKline. No payment was requested nor provided for this work.

    Read all letters published for this article

    Submit response
  5. Indoor vaping and brochodilator use are not analogous

    NOT PEER REVIEWED Bauld et al [1] draw an analogy between indoor vaping and the use of bronchodilators for asthma ("if and when vapour products with a medicinal license become available, it will be important to allow their use indoors, just as asthma inhalers, which dispense a drug and propellants into the atmosphere, can be used indoors.")

    Surely, they cannot be serious here?

    Newman et al showed the amount of dosed drug exhaled by asthmatics ranged from just 0.2%-1.7% across different puffing behaviours [2]. A typical person who uses an asthma puffer would be unwise to use it more than 4-6 times a day [3] whereas vapers can take up to 610 puffs a day, with an average of around 200 [4].

    Conversely, the objective of many ENDS users is the absolute opposite. As this article puts it "At the end of the day, Sub Ohm vaping comes down to three words: big ass clouds" [5] Etter [6] notes that "These newer devices deliver more power, more cloud density, [my emphasis] more intense flavors and a better 'throat hit' than older models."

    With this generation of ENDS becoming more popular, we would expect to see clouding increase. As we know [7], many vapers in a room can send particle counts above those recorded in room where smoking is allowed.

    There is simply no comparison between the asthma medication and propellant a few asthmatics might exhale into (for example) a crowded bar over a few hours and what potentially dozens of vapers could generate in the sort of exuberant clouding sessions that vaping in bars can entail. And unlike vapers, asthmatics do not participate in asthma puffer social events.

    This vaper puts things plainly https://www.youtube.com/watch?v=6c5Ln69hWUc

    References

    1. Bauld L, McNeill A, Hajek P, Britton J, Dockrell M. E-cigarette use in public places: striking the right balance. Tob Control 2016; doi:10.1136/tobaccocontrol-2016-053357

    2. Newman SP, Weisz AWB, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 1991; 46:712-16.

    3. Partners Healthcare. Asthma Center. Chapter 33: How many times a day can I safely use my bronchodilator inhaler? http://www.asthma.partners.org/NewFiles/BoFAChapter33.html

    4. Martin E, Clapp PW, Rebuli ME et al . E-cigarette use results in suppression of immune and inflammatory-response genes in nasal epithelial cells similar to cigarette smoke. merican Journal of Physiology - Lung Cellular and Molecular Physiology Published 10 June 2016 Vol. no. , DOI: 10.1152/ajplung.00170.2016

    5. Kriegel D. What is sub ohm vaping? Our sub ohm vaping guide & tips http://vaping360.com/what-is-sub-ohm-vaping-and-the-dangers-of-sub- ohm-vapes/ 2015;May 26.

    6. Etter J-F. A longitudinal study of cotinine in long-term users of e-cigarettes. Drug and Alcohol Dependence 2016;160:218-221.

    7. Soule EK, Maloney SF, Spindle TR, et al. Electronic cigarette use and indoor air quality in a natural setting. Tob Control 2016;???. doi:10.1136/tobaccocontrol-2015-052772

    Conflict of Interest:

    None declared

    Read all letters published for this article

    Submit response
  6. Internet cigarette vendors make tax free claims and selling cigarette cheaper:An alarming isssue

    NOT PEER REVIEWED The Internet is widely used source for purchasing and selling products. However,purchasing tobacco products online is a new trend. The internet vendors are often exempted from taxes leading to lowering the cost of cigarettes in certain countries.This is a really alarming situation as it would lead to increase in sales of tobacco products due to lower prices. Countries need to check this trend otherwise all the gain achieved till now through legislation and commitments to reduce tobacco consumption could be lost.

    Conflict of Interest:

    None declared

    Read all letters published for this article

    Submit response
  7. Intent-to-treat analysis of observational studies assessing electronic cigarettes' efficacy as an aid to smoking cessation.

    NOT PEER REVIEWED In the last decade, electronic cigarettes (EC) have become increasingly popular in particular among smokers. Most EC users choose to use nicotine containing liquids (electronic nicotine delivery system, ENDS); these ENDS can be considered as similar to nicotine replacement therapies. Among the several questions EC use raises, one is of major importance: Are EC a smoking cessation aid and if yes to what extent compared to existing pharmacotherapies such as nicotine replacement therapies, varenicline or bupropion? Several systematic reviews tried to approach the role of EC as a smoking cessation aid. As of today, only two randomized trials assessed the efficacy of EC with controversial results (1,2). As an editorial (3) and the last systematic review (4) concluded, because of the absence of well- designed and sufficiently powered randomized, controlled, head-to-head therapeutic trials the current accumulation of data originating essentially from observational studies does not allow us to make any conclusion as to EC's therapeutic efficacy in smoking cessation. Manzoli et al. (5, 6) assessed abstinence from tobacco cigarettes or tobacco and electronic cigarettes ('any product') in a prospective cohort study. They included at baseline EC only users, individuals using tobacco cigarettes and EC (dual use) and those using only tobacco cigarettes. They reported the 12-month (5) and 24-month (6) results in two separate papers the latter published online in the June 2016 issue of Tobacco Control. For both papers, the analyses were restricted to individuals whose data were available at 12 or 24 months (completers). This study raises the question whether observational studies assessing efficacy should be analyzed similarly to randomized efficacy trials for which the gold standard approach is the intent-to treat-analysis (ITT) (7) which defines the population submitted to the main data analysis. Table 1. https://docs.google.com/document/d/1RM5mvK1s85N1iZZ_kKiHkKiMsS1SVl4YMPTj6ALHvS8/edit?usp=sharing compares Manzoli et al. results for the 12-month and 24-month abstinence outcomes (5,6). For all baseline categories, completers' abstinence rates are higher than abstinence rates of the baseline population that we can call here as the "ITT" population i.e. of all individuals included. Of particular interest is that EC only users had higher tobacco cigarettes but not 'any product' abstinence rates both at 12 and 24 months than the two other groups. The (unadjusted) "ITT" tobacco cigarettes abstinence rates are 42% and 40.8 % versus the completers abstinence rates of 61.9% and 61.1 % at 12 and 24 months, respectively; all higher than among dual users or tobacco cigarette only users suggesting that EC can be an aid to quit smoking. Unfortunately, both papers report only confounder adjusted odds ratios for completers and not for the "ITT" population. Observational studies looking for treatment efficacy could be analyzed like randomized efficacy trials (8,9) to narrow the gap between randomized clinical trials and observational data (8). Non-ITT, usually completer analyses, aim to estimate the effect of treatments received as opposed to treatments assigned under the ITT approach and by this exclude all factors contributing to non-completion of the trial (lost to follow up, adverse events, discontinuation for any reasons). The advantage of the ITT analysis is that it evaluates the true treatment effect which is the sum of the biological effects, positive or negative such as adverse events, and study adherence. The limitation of the ITT analysis of randomized efficacy trials is the underestimation of efficacy because of non- treatment related confounders (e.g. lost to follow-up for moving to another city). On the other hand, completer analysis overestimates efficacy by ignoring e.g. discontinuation because of adverse events and cannot, therefore, help to assess the benefit/risk ratio of a given intervention. Until results of high-quality, large-scale, comparative, randomized trials of EC' efficacy will be available, data of well conducted prospective observational studies as that of Manzoli at al. (5,6) could estimate EC's efficacy by analyzing "ITT" data and not completers' data while adjusting for all available and potential confounders. Thus, in the Manzoli et al. study (5,6) adjusted "ITT" population abstinence rates would have provided more convincing results about EC's efficacy as an aid for smoking cessation than completers' adjusted abstinence rates. REFERENCES 1. Caponnetto P, Campagna D, Cibella F, et al. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One. 2013 Jun 24;8(6):e66317. doi: 10.1371/journal.pone.0066317. Print 2013. 2. Bullen C, Howe C, Laugesen M, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet. 2013 Nov 16;382(9905):1629-37. doi: 10.1016/S0140-6736(13)61842-5. Epub 2013 Sep 9. 3. Bernstein SL. Electronic cigarettes: more light, less heat needed. Lancet Respir Med. 2016; Feb;4(2):85-7. doi: 10.1016/S2213-2600(16)00010- 2. Epub 2016 Jan 14 4. Malas M, van der Tempel J, Schwartz R, et al. Electronic Cigarettes for Smoking Cessation: A Systematic Review. Nicotine Tob Res. 2016 Apr 25. pii: ntw119. [Epub ahead of print] Review. 5. Manzoli L, Flacco ME, Fiore M, et al. , Electronic cigarettes efficacy and safety at 12 months: Cohort Study. PLoS One. 2015 Jun 10;10(6):e0129443. doi: 10.1371/journal.pone.0129443. eCollection 2015. 6. Manzoli L, Flacco ME, Ferrante M, et al. Cohort study of electronic cigarette use: effectiveness and safety at 24 months. Tob Control. 2016 Jun 6. pii: tobaccocontrol-2015-052822. doi: 10.1136/tobaccocontrol-2015- 052822. [Epub ahead of print] 7. Detry MA, Lewis RJ. The Intention-to Treat principle. How to assess the true effect of choosing a medical treatment. JAMA 2014; 312:85-86. 8.Wilcox A, Wacholder S. Observational data and clinical trials. Narrowing the gap? Editorial. Epidemiology 2008;19: 765. 9. Herna?n MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19:766-779.

    Conflict of Interest:

    None declared

    Read all letters published for this article

    Submit response
  8. Impact of e-cigarette adverts on children's perceptions of smoking

    NOT PEER REVIEWED The study conducted in England by Petrescu and colleagues [1] concludes that there is a "potential for e-cigarette adverts to undermine tobacco control efforts by reducing a potential barrier (i.e. beliefs about harm) to occasional smoking". Clearly it is important to keep monitoring the impact of advertising, particularly on children, and this research paper is a welcome contribution. However, it is important to put this in context.

    The most recent survey of smoking among children in England found the lowest recorded smoking rates among youth aged 11-15 since records began in 1982.[2] It's worth noting that rates have continued to fall since e- cigarette use and marketing of products began to take off in Great Britain after 2010.[3][4] In 2010, 5% of 11-15 year olds were regular smokers falling to 3% in 2014. Also, in 2010 27% had ever tried smoking, falling to 18% in 2014.

    So it doesn't appear that e-cigarette advertising in England has had an impact so far on the number of children trying smoking, or becoming regular smokers. Furthermore from May 2016 all cross border advertising including TV, radio, internet and newspaper advertising has been banned throughout the European Union, thereby limiting advertising to that with local impact.

    It should also be noted that in the UK e-cigarette manufacturers are required to adhere to strict rules on advertising content.[5] These rules specify in particular that advertisers must ensure ads do not target, feature or appeal to children; that they do not confuse e-cigarettes with tobacco products; that they do not mislead with regard to product ingredients.

    In jurisdictions where e-cigarette ads are unregulated and resemble tobacco promotion, it's reasonable to assume that they could affect children's perceptions of both e-cigarettes and smoking. This study underlines the need to monitor e-cigarette marketing but the potential risks that e-cigarette advertisements are undermining tobacco control efforts in England are likely to be over-stated.

    [1] D C Petrescu, M Vasiljevic, J K Pepper, K M Ribisl, T M Marteau. What is the impact of adverts on children's perceptions of tobacco smoking? Tobacco Control published online 6 Sept. 2016. Doi: 10.1136/tobaccocontrol-2016-052940

    [2] Smoking, drinking and drug use among young people in England in 2014. Health & Social Care Information Centre, 2015.

    [3] ASH Fact sheet. Use of electronic cigarettes (vapourisers) among adults in Great Britain. ASH, 2016

    [4] De Andrade M et al. The marketing of e-cigarettes in the UK. Cancer Research UK, 2013. https://www.cancerresearchuk.org/sites/default/files/cruk_marketing_of_electronic_cigs_nov_2013.pdf

    [5] Committee on Advertising Practice. https://www.cap.org.uk/Advice-Training-on-the-rules/Advice-Online- Database/Electronic-cigarettes.aspx#.V86Snf_6uvE

    Conflict of Interest:

    None declared

    Read all letters published for this article

    Submit response
  9. Indoor air laws and hookah smoking

    NOT PEER REVIEWED.
    The authors rightly point out that loopholes exist in some smoke-free air laws, exempting smoking of "tobacco-free or herbal hookah products" in public places.
    In New York City, where this study took place, the governing laws are: (1) New York State Clean Indoor Air Act, and (2) New York City Smoke Free Air Act.[1] Between 2002-2003, both laws were amended to "prohibit smoking in virtually all indoor places in New York State where people work or socialize."[2] The changes were made "in response to mounting scientific evidence that links exposure to the airborne smoke that is a by-product of smoking . . . to serious health risks to non-smokers."[3] Unfortunately, smoking was narrowly defined as "the burning of a lighted cigar, cigarette, pipe or any other matter or substance which contains tobacco."[4] Thus, giving rise to New York's loophole allowing non-tobacco hookah smoking.
    By comparison, the situation is different in neighboring New Jersey. In 2006, the state legislature enacted the New Jersey Smoke-Free Air Act prohibiting smoking in public places.[5] In the Act, smoking is defined as "the burning of, inhaling from, exhaling the smoke from, or the possession of a lighted cigar, cigarette, pipe or any other matter or substance which contains tobacco or any other matter that can be smoked."[6] New Jersey courts have interpreted the Act to include regulation of hookah bars - even when non-tobacco products are used in these devices. [7] Constitutional challenges to overturn this statute have failed underscoring its strength.
    Weakly worded "smoking" definitions are a chief source of statutory loopholes allowing public use of hookahs, as well as electronic cigarettes. Advocates for stronger clean indoor air laws should consider developing a model rule with commentary containing explanations and examples. This lays a foundation to assist legislators in statutory creation and helps judges with interpretation. Such model rules exist for many other areas of the law. States are free to adopt model rules in whole or in part. Smoking in the "new age" encompasses modalities not in existence when many smoking prohibitions were enacted. Vigilance is needed to ensure anti-smoking laws keep pace with the times.

    References [1] New York City C.L.A.S.H. v. City of New York, 315 F. Supp. 2d 461, 465 (2004).
    [2] Id. at 466.
    [3] Id. at 466-67.
    [4] N.Y. Pub Health Law 1399n(8) (Consol. 2003) (emphasis added).
    [5] N.J. Stat. 26:3D-55-64.
    [6] N.J.S.A. 26:3D-57
    [7] See State v. Badr, 415 N.J. Super 455 (2009).

    Read all letters published for this article

    Submit response

Free sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of Tobacco Control.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.


This insightful video is produced by Cancer Research UK